Compound 60 has a very significant affinity to MDM2 (Ki < 1 nM), powerful mobile action, and a very good oral pharmacokinetic profile. Compound 60 is able to achieving entire and extended-Long lasting tumor regression in vivo and it is now in phase I medical trials for most cancers therapy. https://chiefb974swa8.activosblog.com/profile